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Abstract
Different brain regions sense and modulate the counterregulatory responses that can occur in response to declining plasma
glucose levels. The aim of this study was to determine if changes in regional cerebral blood flow (rCBF) during
hypoglycemia relative to euglycemia are similar for two imaging modalities–pulsed arterial spin labeling magnetic
resonance imaging (PASL-MRI) and positron emission tomography (PET). Nine healthy non-diabetic participants underwent
a hyperinsulinemic euglycemic (9263 mg/dL) – hypoglycemic (5361 mg/dL) clamp. Counterregulatory hormone levels
were collected at each of these glycemic levels and rCBF measurements within the previously described network of
hypoglycemia-responsive regions (thalamus, medial prefrontal cortex and globus pallidum) were obtained using PASL-MRI
and [15O] water PET. In response to hypoglycemia, rCBF was significantly increased in the thalamus, medial prefrontal
cortex, and globus pallidum compared to euglycemia for both PASL-MRI and PET methodologies. Both imaging techniques
found similar increases in rCBF in the thalamus, medial prefrontal cortex, and globus pallidum in response to hypoglycemia.
These brain regions may be involved in the physiologic and symptom responses to hypoglycemia. Compared to PET, PASL-
MRI may provide a less invasive, less expensive method for assessing changes in rCBF during hypoglycemia without
radiation exposure.
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Introduction
Hypoglycemia is a devastating problem for people with diabetes
and accounts for 6–10% of all deaths of people with Type 1
diabetes [1]. Recurrent hypoglycemia in diabetes occurs due to the
interplay between therapeutic hyperinsulinemia and compromised
counterregulatory and symptom responses to falling plasma
glucose levels. This can lead to hypoglycemia associated
autonomic failure (HAAF) and can cause a vicious cycle of
repeated hypoglycemia [2,3]. The exact mechanisms involved in
the normal physiologic responses to hypoglycemia as well as their
impairment in HAAF are not well known. A group of brain
regions with glucose-sensing cells has been hypothesized to be
involved [4]. These cells are unique in that they are able to
translate a fall in extracellular glucose into a change in
neurotransmitter or hormone release [5]. Thus, better delineation
of this hypoglycemic network and how it is integrated into the
hypoglycemic responses is key in order to develop novel
therapeutic interventions that prevent recurrent hypoglycemia or
improve hypoglycemia awareness in type 1 diabetes.
Changes in regional cerebral blood flow (rCBF) in response to
hypoglycemia have been assessed using [15O] water positron
emission tomography (PET) [4,6,7,8]. Regional increases in rCBF
may reflect increases in neuronal activity due to rises in synaptic
metabolic activity but not spike firing rate [9,10,11]. Observed
increases in synaptic activity in response to hypoglycemia, have
been reported using PET within a discrete network of inter-
connected brain regions that included the medial prefrontal
cortex, orbitoprefrontal cortex, globus pallidus, thalamus, and
periaqueductal grey matter [4]. These same regions are involved
in modulating visceral responses [12]. In addition, increased rCBF
has been observed in the dorsal midline thalamus during recurrent
hypoglycemia, accompanied by attenuated counterregulatory
responses due to HAAF [6]. While hypoglycemic changes in
rCBF have primarily been assessed by PET, this imaging
technique has significant limitations including the need for
a cyclotron, significant expense, and the injection of a radiolabeled
tracer thus limiting the number of studies that can be performed in
a particular subject and restricting studies to adults only. More
recently, non-invasive MRI methods have been developed to
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assess rCBF [13] and provide comparable CBF quantification
between PET and ASL; at least in euglycemia [14].
In the pulsed arterial spin labeling magnetic resonance imaging
(PASL-MRI) method, arterial blood water is magnetically labeled
just proximal to the region (slice) of interest. Water molecules
within this portion of arterial blood are labeled magnetically. This
‘paramagnetic tracer’ flows into a slice of interest and exchanges
with tissue water. The inflowing blood water alters tissue
magnetization. During this time, the ‘‘tag’’ image is obtained.
This process is then repeated without labeling arterial blood to
create the ‘‘control’’ image. The difference between the ‘‘control’’
and ‘‘tag’’ image produces a perfusion image which reflects the
amount of arterial blood delivered to each voxel within the slice
within the transit time. PASL-MRI provides reproducible and
reliable quantitative CBF measurements across the brain. Com-
pared to PET, PASL-MRI is completely noninvasive, less
expensive, has no radiation exposure risk, is performed without
gadolinium, thus bypassing concerns regarding nephrogenic
systemic fibrosis in patients with significant renal insufficiency
and can be repeatedly performed on the same subject and on
subjects of any age with great ease [15]. However, this technique
has been used in only a limited number of clinical applications (i.e.
brain tumors, Alzheimer’s Disease or stroke) [16,17,18] and has
not been widely used to study hypoglycemia or HAAF [19,20].
The aim of this study was to determine, using a within subjects
study design, if PASL-MRI can detect a pattern of changes in
rCBF due to hypoglycemia similar to that previously-observed
with PET.
Research Design and Methods
Ethics Statement
The study was approved by the Washington University in Saint
Louis (WUSTL) Human Research Protection Office. Each
participant gave his or her written consent to participate in this
study. All clinical investigation was conducted according to the
principles expressed in the Declaration of Helsinki.
Subjects
Nine healthy adult individuals (4 women and 5 men) who were
mean 6SE age 29.762.6 years and mean body mass index (BMI)
24.261.1 kg/m2 were recruited through volunteers for health
program at (WUSTL). All subjects were right handed and in good
health, based on a medical history and physical examination.
None were taking medications (aside from an oral contraceptive)
that could affect rCBF or counterregulation. All had normal
fasting plasma glucose, creatinine and hematocrit. None of the
individuals had a personal or family history of diabetes in first
degree relatives. None had a personal history of significant
psychiatric, neurological, or cardiovascular conditions.
Experimental Design
Participants were studied in the morning after a 10-hour
overnight fast. They remained supine throughout the study. Two
intravenous catheters were inserted into arm veins (one for
infusion of insulin and dextrose and the other for injection of
radioactive isotope) and one intravenous catheter was inserted into
a dorsal hand vein that was kept in a ,55uC plexiglass box (for
arterialized venous sampling). All nine subjects underwent
a hyperinsulinemic (regular human insulin, Novo Nordisk,
Bagsværd, Denmark in a dose of 2.0 mU?kg21?min.21) eu-
glycemic (9263 mg/dL [5.1 mmol/L] ,2 hours) and then
hypoglycemic (5361 mg/dL [3.0 mmol/L]) x,2 hours) clamp
procedure using variable infusions of 20% dextrose based on
plasma glucose determinations (YSI Glucose Analyzer 2, Yellow
Springs Instruments, Yellow Springs, OH) every five minutes
(Figure 1). During the euglycemic period, two PASL-MRI
measurements of rCBF were obtained. In the second hour of
euglycemia, [15O]water PET measurements were performed four
times at 15 minute intervals. Hypoglycemia was then induced and
PET measurements were obtained four times at 15 minute
intervals. Two PASL-MRI measurements were obtained at the
end of the hypoglycemic clamp. Each participant was moved
between the PET and MRI scanners quickly while maintaining
hypoglycemic and euglycemic conditions. All scans were obtained
after the subject had reached at least 20 minutes of steady state at
the desired glycemic level. Every 30 minutes, arterialized venous
samples were drawn for analytes (glucose, insulin, glucagon,
epinephrine, norepinephrine) and blood pressures and heart rates
were recorded. Throughout the study cardiac function was
monitored using an electrocardiogram.
The severity of the hypoglycemic symptoms was determined
every 30 minutes during the euglycemic - hypoglycemic clamp
with a validated questionnaire [21]. Subjects were asked to score
(from 0, none, to 6, severe) six neurogenic (autonomic) symptoms
(heart pounding, shaky/tremulousness and nervous/anxious (ad-
renergic) and sweaty, hungry and tingling (cholinergic)) and six
neuroglycopenic symptoms (difficulty thinking/confused, tired/
drowsy, weak, warm, faint and dizzy) [21].
Analyte Measurements
Plasma glucose concentrations were measured with a glucose
oxidase method (YSI Glucose Analyzer, Yellow Springs Instru-
ments, Yellow Springs, OH). Plasma insulin concentrations were
measured with a two site chemiluminescent assay (Immulite 1000,
Siemens Corp, Los Angeles, CA). Counterregulatory hormones
including plasma epinephrine and norepinephrine were measured
with a single isotope derivative (radioenzymatic) method [22] and
plasma glucagon concentrations were measured with a radioim-
munoassay (Millipore, Temecula, CA).
Magnetic Resonance (MR) Imaging Acquisition
All MRI imaging was performed on a 1.5T Siemens Avanto
System (Erlangen, Germany) with a 12 channel radiofrequency
head coil. To enable computation of rCBF, a total of four
proximal inversion with control for off-resonance effects (PICORE
Q2) PASL-MRI perfusion scans (3 minutes in duration) were
collected with two at the initiation of euglycemia and two more at
the end of the hypoglycemic clamp. Scanning parameters were
TR = 2500 ms, TE = 13.0 ms, TI1 = 700 ms, TI2 = 1800 ms, flip
angle = 90u, 100 mm tag with a 10 mm gap between the tag and
the imaging slice, FOV = 256 mm, 4.064.068.0 mm voxels. A
total of 140 PASL-MRI frames (or 70 PASL-MRI pairs) were
analyzed for each subject. One high-resolution Tı-weighted
magnetization-prepared rapid gradient echo (MPRAGE)
[TR = 2400.0 ms, TE = 3.23 ms TI = 1000.0 ms, flip angle = 8u,
16161 mm voxels] structural scan was also obtained for
anatomical region definition and facilitate image alignment.
PET Scan Acquisition
General details of the [15O]water PET acquisition and analysis
methods have been previously reported in detail in prior
publications [6]. All PET images were acquired with a Siemens/
CTI (Knoxville, TN) EXACT HR+962 tomograph using the two-
dimensional mode (interslice septa extended). Subjects were
positioned in the scanner so that the entire brainstem was
included within the 15 cm axial field of view. A transmission scan
was collected at each scan session for PET data reconstruction.
CBF Responses to Hypoglycemia Using PASL and PET
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Four boluses of 50 mCi of [15O]water (1.85 GBq) were injected at
15 minute intervals [23,24,25] during euglycemia and repeated
during hypoglycemia and 40-second emission scans were collected
to measure relative rCBF.
MR Image Post-Processing
In order to evaluate the PASL-MRI data, we developed a suite
of in-house image processing utilities following previously estab-
lished best practices [26]. The two PASL-MRI image series for
each subject were cross-aligned and motion-corrected according to
a rigid body algorithm using a program developed in-house [27].
‘‘Tag’’ and ‘‘control’’ images were pairwise subtracted to obtain
mean perfusion images. CBF was calculated for each mean
perfusion image using the following formula [28,29].
f~
lDM
2aM0TI1 exp {TI2=T1að Þ
Where DM is a perfusion image calculated by pairwise subtraction
of label and control images, M0 represents the image intensity of
brain tissue at magnetic equilibrium, a represents the efficiency of
tag delivery, l is blood/tissue water partition coefficient, T1a is the
longitudinal relaxation time of blood, and TI1 and TI2 are the
time required to deliver the tag and the time required to collect the
image, respectively. The following values were used for this study:
a= 0.98, l= 0.9 mL/g, T1a = 1.6 s [29].
In order to use PASL-MRI and PET methodology to assess if
regional changes in rCBF occur in a-priori regions previously
reported to have increased synaptic activity during hypoglycemia,
each subject’s MPRAGE was segmented using FreeSurfer’s
segmentation and cortical reconstruction analysis software pack-
age (Freesurfer Version 5.1 developed at the Martinos Center,
Harvard University, Boston, MA; http://surfer.nmr.mgh.harvard.
edu) [30,31,32]. Our regional analysis primarily focused on
a network of brain areas [including the thalamus (thalamus
proper), medial prefrontal cortex (rostral anterior cingulate), right
orbital prefrontal cortex and globus pallidum] (Figure 2) that have
been shown to have increased blood flow during hypoglycemia
with PET [4]. Mean rCBF of each of these regions was obtained
for both glycemic conditions.
PET Scan Analyses
PET images were reconstructed using filtered back-projection
technique [33]. All individual PET images were co-registered
using standard technique [34] and normalized to a whole brain
CBF of 50 mL/100 g/min. For each participant, the PET scans
were registered to corresponding MPRAGE images using a vector-
gradient based method [35]. Images from each glycemic
conditions for individual subject were averaged to increase
statistical precision [36]. The same regional analysis approach as
the PASL-MRI data was used for PET CBF analysis.
Voxel-wise Analysis of rCBF in PET and PASL-MRI
To allow between-subject voxel-wise comparison of PET and
PASL-MRI, each subject’s MPRAGE data were warped to the
1988 Talairach atlas [37]. In order to eliminate anatomical
differences as a possible confound in our analysis, a common atlas
space was computed through an affine cross-registration of the
Talairach-conformed structural scans from each individual subject
[38]. For this analysis, the second PASL-MRI scan was aligned to
Figure 1. Schematic diagram of experimental protocol. Counterregulatory hormone levels, hypoglycemic symptom scores and rCBF
measurements were obtained during the hyperinsulinemic euglycemic – hypoglycemic clamp. rCBF measurements were obtained using PASL-MRI
and [15O]water PET for healthy individuals (n=9).
doi:10.1371/journal.pone.0060085.g001
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the first PASL-MRI scan. The PASL-MRI scans were aligned to
a study-specific derived atlas. Each computed rCBF map (whether
PET or PASL-MRI) was transformed to this study-specific atlas
space after rCBF computation [26]. A voxel-wise comparison of
rCBF for the two conditions (euglycemia vs. hypoglycemia) was
carried out separately for PET and PASL-MRI.
Statistical Analysis
rCBF and relevant systemic variables were compared across
conditions (during euglycemia vs. during hypoglycemia) using
a paired t-test. P values less than 0.05 were considered significant.
Hypoglycemia and euglycemia rCBF measures were expressed as
means and SE. Coefficient of variation (COV) for each imaging
method was calculated by computing the average SD of the rCBF
from a particular region of interest (ROI) and dividing it by the
mean of the rCBF from that area.
Results
Counterregulatory Hormone and Symptom Responses
During the hypoglycemic clamp plasma epinephrine responses
(3064 vs 348637 pg/mL, p,0.0001), plasma glucagon (4063 vs
9163 pg/mL, p = 0.001), and cortisol (1061 vs 2162 mg/dL,
p = 0.001) levels were significantly increased compared to eu-
glycemia. Insulin levels during euglycemia were 16064 vs 15965
during hypoglycemia (p = 0.6). Hypoglycemic symptom scores
significantly increased during hypoglycemia (260.4 vs 962,
p = 0.005) (Table 1).
Regional Cerebral Blood Flow
During hypoglycemia, rCBF significantly increased within
many ROIs for both PET and PASL-MRI (Figure 3). A significant
increase in rCBF was confirmed in the thalamus (p = 0.003,
p = 0.02), medial prefrontal cortex (p = 0.03, p = 0.01) and globus
pallidum (p = 0.001, p = 0.01) during hypoglycemia compared to
euglycemia for both PET and PASL-MRI respectively (Figure 4).
The coefficient of variation across the ROI for PET was 6% and
12% for PASL-MRI, which are comparable between the two
methods.
A Voxel-wise analysis of the brain using FreeSurfer’s general
linear model tool was utilized to assess if certain brain regions were
significantly increased for hypoglycemia for both methods. The
only region that survived a multiple comparison analysis by both
PASL-MRI and PET was the thalamus.
Discussion
A fall in blood glucose level below ,80 mg/dL induces a rapid
counterregulatory response to restore euglycemia. This process
involves the activation of peripheral and central glucose-sensing
units involved in the physiological control of counterregulation.
The mechanisms by which some patients with diabetes develop
impaired responses to hypoglycemia remain unclear. A better
understanding of these changes and the brain regions involved in
the central integration of these responses, might allow targeted
therapies aimed at preventing the loss of these responses in HAAF,
and allow diabetic patients safer glycemic control. Our findings
demonstrate that acute hypoglycemia activates the thalamus, the
medial prefrontal cortex and the globus pallidum, as has
previously been shown in studies using [15O]water PET [4].
These regions mediate autonomic responses to various visceral
stimuli and may facilitate mechanisms due to hypoglycemia
[39,40,41,42]. Although our study does not allow us to examine
whether the changes seen in rCBF lead to the specific hormonal
changes, based on prior studies, the thalamus has connections to
the hypothalamus that can regulate the sympathoadrenal outflow
during hypoglycemia, and its activation seem to be independent of
awareness and be involved primarily with counterregulatory
responses to hypoglycemia [7]. Meanwhile, the medial prefrontal
cortex seems to be involved in counterregulation [8] and
symptomatic awareness of hypoglycemia, and its activation during
acute hypoglycemia may be caused by hypoglycemia per se, rather
than by counterregulation [43]. Further studies are needed to
outline the hierarchy of activation of brain regions and its
association with hypoglycemic physiological and behavioral
responses.
That we only found significant increases in rCBF in the
thalamus using a voxel wise approach by both ASL and PET, does
not mean that the increases in rCBF in the other regions found in
the regional analysis are incorrect. A voxel-wise whole brain
analysis is less sensitive in detecting changes in a priori identified
Figure 2. Free Surfer regions of interest. Free Surfer maps of ROI used for this analysis. A) Sagittal (top) B) Axial (bottom) view of Freesurfer ROIs.
Blue: globus pallidum, Green: caudate, Dark Green: lateral prefrontal cortex, Magenta: medial prefrontal cortex.
doi:10.1371/journal.pone.0060085.g002
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regions due to correction for multiple comparisons and a factor of
multiple thresholding across the entire brain space.
Although PASL-MRI has been already used in hypoglycemia
studies [19,20], this study documents that PASL-MRI is a reliable
method that can be used to study activation of the hypoglycemia
network in a noninvasive manner since our work is the first to
compare this technique to the gold standard in both conditions.
PASL-MRI has several advantages, including that it is a less
invasive and expensive method compared to PET, it does not
require placement of an arterial line or any radiation exposure,
and the scanning time can be shorter so that successive rCBF maps
using PASL-MRI can be acquired on the same subject. These
significant advantages encourage extension of this noninvasive
imaging methodology to future pediatric studies (where less
invasive methodologies are preferred) as well as to other studies
of healthy and diabetic individuals, which seek to study
hypoglycemia-associated recruitment of brain regions and other
hypoglycemia-associated physiological responses more broadly.
Being able to study children, particularly diabetic children, offers
better opportunities to understand the early loss of counter-
regulatory response in recurrent hypoglycemia by allowing us to
follow the full course of diabetes. However, limitations exist for
PASL-MRI. It can only be performed on patients that can tolerate
MRI and have no braces or metal implants that wouldn’t limit the
implementation of this technique. This technique also requires
a very high signal-to noise ratio and cannot accurately map either
low (,10 mL/100 g/minute) or high (.150 mL/100 g/minute)
rCBF states [13].
The most important finding of our work is the consistent
increase in rCBF due to hypoglycemia in the same regions across
both imaging methods. Our work suggests that there is presence of
a cerebral network involved in the hypoglycemic responses and
Table 1. Mean (6SE) plasma glucose and counterregulatory hormones at baseline and at time of CBF acquisition for euglycemic





acquisition Peak value Mean at Baseline
Mean during CBF
acquisition Peak value
Glucose (mg/dl) 9161 9263 101 5461 5361 58
Insulin 1061 16064 244 158616 15965 238
Epinephrine (pg/ml) 2568 3064 95 353626 348637 517
Glucagon (pg/ml) 5967 4063 62 85611 9163 169
Cortisol (mg/dl) 961 1061 17 1762 2162 42
Symptoms 160.3 260.4 4 962 962 22
doi:10.1371/journal.pone.0060085.t001
Figure 3. Qualitative cerebral blood flow during hypoglycemia and euglycemia in PET and PASL-MRI. Axial images showing the mean
difference (CBF hypoglycemia – CBF euglycemia) maps from nine subjects for A) positron emission tomography (PET) and B) pulse arterial spin
labeling magnetic resonance imaging (PASL-MRI). Yellow/orange represents increased and blue represents decreased blood flow during the
hypoglycemic relative to euglycemic session. Similar increases in CBF for hypoglycemia were seen for both methods within the thalamus.
doi:10.1371/journal.pone.0060085.g003
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demonstrates the ability to use this novel MRI method in a reliable
manner to study these responses.
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